stent related symmptoms. Tadalafil has recently been proven to be effective in LUTS. We demonstrate the effect od tadalafil in stent related symptoms in comparison with Tamsulosin.
INTRODUCTION AND OBJECTIVES:
Bleeding is one of the most unpredictable and threatening complication during PCNL. Tranexamic acid (TXA), an antifibrinolytic agent, has proven to reduce blood loss and mortality in trauma and elective surgeries. We aimed to evaluate the impact of intraoperative use of TXA on PCNL transfusion rate, blood loss and effectiveness.
METHODS: We conducted a single-center, double-blinded, randomized, placebo controlled trial, from May 2016 to August 2018. Eligible participants were adult stone formers with complex stones (Guy's 3 and 4). Participants were registered prospectively and randomized in a 1:1 ratio. Intervention group received 1g of TXA at anesthesia induction. The control group received placebo. The main outcome measure was perioperative blood transfusion rate. The secondary outcome included hemoglobin drop, complications and stone-free rate (SFR). Patient, surgeon and anesthesiology team were blinded to intervention assignment. The intention-to-treat analyses was employed. Data were securely stored electronically using REDCapTM software. ClinicalTrials.gov identifier NCT02966236.
RESULTS: A total of 128 subjects were included in the study. The recruitment rate was 100% and 98.4% completed the study. Treatment groups were balanced with respect to baseline patient demographics, stone features and operative parameters. The lower transfusion rate in TXA group demonstrated a trend toward significance compared to placebo (3.2% vs. 11%; p[0.08) . Post-hoc analysis demonstrated that hemoglobin concentrations at 3 moments after surgery (at the end of surgery, 12h, and 24h) were statistically higher in the intervention group compared to placebo (Fig. 1) . The volume of intravenous fluids and operative time were similar in both groups. SFR was statistically higher in the TXA group (p[0.01). No adverse reaction was reported. During the 30day follow-up period, we recorded one thromboembolic event, restricted to the TXA group.
CONCLUSIONS: The intraoperative use of TXA during PCNL for complex stones is safe and effective in reducing perioperative blood loss and transfusion rate. Moreover, TXA use contributes to better stone clearance than placebo.
There remains lack of agreement on the optimal mpMRI prostate cancer scoring system with recent UK consensus recommending use of 5-point Likert assessment rather than PI-RADS. Using a paired cohort study design we compared clinical validity and utility of both scoring systems in the detection of clinically significant (cs) and insignificant (ci) prostate cancer (PCa).
METHODS: 329 pre-biopsy mpMRI scans in consecutive patients underwent prospective paired reporting using both Likert and PI-RADS (v2) by expert uro-radiologists. Patients were offered biopsy for any Likert or PI-RADS score !3; a score of 3 required PSAdensity !0.12ng/ml/ml. Utility was evaluated in terms of proportion biopsied, and proportion of csPCa and ciPCa detected. In those patients biopsied, overall accuracy of each system was assessed using receiver operating characteristic (ROC) curves. The primary threshold of csPCa was Gleason !3þ4; secondary thresholds of !Gleason 4þ3, Ahmed/UCL1 (Gleason !4þ3 or maximum cancer core length (CCL) !6 or total CCL !6) and Ahmed/UCL2 (Gleason !3þ4 or maximum CCL !4 or total CCL !6) were also used.
RESULTS: Median age was 66 (IQR: 13) and PSA was 8 (IQR: 6). A similar proportion of men met the biopsy threshold and underwent biopsy in both groups (69.3% vs. 75.7%). Likert predicted more csPCa than PI-RADS across all disease thresholds. Rates of ciPCa were comparable in each group (Table 1 ). ROC analysis of biopsied patients showed that, although both scoring systems performed well as predictors of csPCa, Likert exhibited higher areas under the curve (AUC) than PI-RADS across all thresholds (Table 2) .
CONCLUSIONS: Both scoring systems demonstrated good diagnostic performance. Overall, Likert was superior by all definitions of csPCa. It has the advantages of being flexible, intuitive and allows inclusion of clinical data. We recommend that its use be considered once radiologists have developed sufficient experience in reporting prostate mpMRI.
Source of Funding: none

PD60-02 CAN THE TIME INTERVAL BETWEEN MRI AND FUSION BIOPSY AFFECT THE CANCER DETECTION RATES?
Maria Becerra*, Miami, FL; Feng Miao, Isildinha Reis, Miami, FL; Daniel Furlong, Taylor Johnson, Nachiketh Soodana-Prakash, Dipen Parekh, Chad Ritch, Bruno Nahar, Mark Gonzalgo, Sanoj Punnen, Miami, FL INTRODUCTION AND OBJECTIVES: Multiparametric MRI fusion guided biopsy (FBx) has been shown to reliably improve the prostate cancer (PCa) detection. We aim to evaluate if the detection of prostate cancer on targeted biopsy varied based on the time interval between the MRI and the FBx.
METHODS: A prospectively maintained database of patient undergoing MRI followed by FBx for elevated PSA between 10/2014 and 07/2018 at our institution was reviewed. Patients with previously diagnosed PCa were excluded from the analysis. Time between MRI and FBx were evaluated as a continuous variable and as categorical variable as follows 5, 5-10, >10 weeks (w). Data were documented on a per lesion basis and each target in the MRI was classified for the level of suspicion of malignancy based on the Prostate Imaging-Reporting and Data System (PI-RADS). Generalized estimating equation models for correlated binary outcome data was fitted to assess the effect of time (or time intervals) between MRI and FBx on the histopathological findings in the defined MRI targets. Separated models were fitted for the detection of any cancer or Gleason 7 or higher PCa (Gleason 7 or greater) with adjustment for relevant characteristics.
RESULTS: A total 1,181 lesions from 806 men were analyzed. Prostate cancer was detected in 34.5% (407) of lesions, with 21.4% (253), 13% (154) and 65.5% (774) of lesions detecting clinically significant cancer (CSC), indolent (Gleason 6) PCa, or benign pathology, respectively. The MRI was performed <5w apart from the FBx in 423 patients, within 5-10 w in 261 and >10w in 122 patients. Adjusting for level of suspicion, previous biopsy result, age at MRI, race/ethnicity and marital status, the detection rates of any or CSC were not statistically different in any of the time intervals between the MRI/FBx (p[0.931 and p[0.538, respectively) . Furthermore, when analyzing time as a continuous variable (per week increase) there was no association between time from MRI to FBx and PCa detection (p[0.849 and p[0.666, respectively) .RESULTS: A total 1,181 lesions from 806 men were analyzed. Prostate cancer was detected in 34.5% (407) of lesions, with 21.4% (253), 13% (154) and 65.5% (774) of lesions detecting clinically significant cancer (CSC), indolent (Gleason 6) PCa, or benign
